Skye Bioscience, Inc.
SKYEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Skye Bioscience, Inc. focuses on Biotechnology services and products. Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Valued at $22.5M, SKYE is a micro-cap name in its sector. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.
Market Cap
$22.5M
Beta
2.94
P/E (TTM)
—
P/E (Fwd)
-0.57
EPS (TTM)
$-1.39
EPS (Fwd)
$-1.13
ROE
-168.0%
ROA
-87.7%
Cash
$17.1M
Total Debt
$311,318
Free CF
-$21.8M
52W Change
-83.5%
Annual Financials
Cash vs Debt
Where SKYE stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, SKYE finished 24.39% below its 150-day moving average ($0.82) and 42.06% below its 200-day moving average ($1.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SKYE overbought or oversold?
At the July 15, 2026 close, SKYE's RSI(14) was 33.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Skye Bioscience, Inc. holds $17.1M in cash against $311K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$21.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -168.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 2.94 means SKYE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SKYE.